It started as a respiratory illness—or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that ...
PEMGARDAâ„¢ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...
and show that they exhibit clinical signs and immunopathology consistent with COVID-19 following infection with SARS-CoV-2, suggesting that human ACE2 transgenic pigs are a viable large animal ...
VirusHB-Chip offers groundbreaking sensitivity in detecting SARS-CoV-2 in plasma, saliva, and stool, transforming COVID-19 diagnostics and treatment strategies.
Get up-to-date information on the dynamics of COVID-19 variants in Toronto. Discover how this research can aid in fighting ...